Health economic modelling approaches in cell and gene therapies
Previous PostKey issues in health economic analysis in NICE Highly Specialised Technology appraisals
Next PostBudget Impact Analysis of Macimorelin, an Oral Growth Hormone Stimulation Test, As a Diagnostic Test for Adult Growth Hormone Deficiency (AGHD) across 5 European Countries